annual meeting program - American Society of Clinical Oncology

SATURDAY
Saturday, June 5, 2010
2:00 PM - 6:00 PM
GENERAL POSTER SESSION
Breast Cancer—Local-Regional and Adjuvant Therapy
Location: S Hall A2
Tracks(s): Breast Cancer
Brd. 1A DEVA: Randomized trial of sequential epirubicin and docetaxel versus
epirubicin alone in node-positive postmenopausal early breast cancer (EBC)
patients. (Abstract #536)
R. C. Coombes, J. M. Bliss, M. Espie, F. Erdkamp, J. J. Wals, A. Tres,
R. E. Coleman, J. Reise, D. Cooper, P. Hupperets
Brd. 1B Long-term results from the neoadjuvant GeparDuo trial: A randomized,
multicenter, open phase III study comparing a dose-intensified 8-week
schedule of doxorubicin hydrochloride and docetaxel (ADoc) with a
sequential 24-week schedule of doxorubicin hydrochloride/
cyclophosphamide followed by docetaxel (AC-Doc) regimen as preoperative
therapy (NACT) in patients (pts) with operable breast cancer (BC). (Abstract
#537)
M. Kaufmann, W. Eiermann, M. Schuette, J. Hilfrich, J. U. Blohmer, B. Gerber,
S. D. Costa, S. Loibl, V. Nekljudova, G. Von Minckwitz, German Breast Group
Brd. 1C An epidemiologic study of the effect of adjuvant radiotherapy on 2D tumor
characteristics and prognosis of contralateral breast cancer (CBC). (Abstract
#538)
M. E. Sandberg, M. Hartman, S. Eloranta, A. Ploner, P. Hall, K. Czene
Brd. 1D The use of Ki67 to predict benefit from adjuvant tamoxifen in node-negative,
estrogen receptor-positive patients. (Abstract #539)
R. Yerushalmi, R. Woods, K. A. Gelmon, C. Speers, P. Ravdin
Brd. 1E Gene signatures as predictors of response to neoadjuvant chemotherapy
(NCT) with docetaxel, doxorubicin, cyclophosphamide (TAC), or AC and
nab-paclitaxel (nab-P) and carboplatin �/- trastuzumab in patients (pts) with
stage II-III and inflammatory breast cancer (IBC). (Abstract #540)
G. Somlo, P. H. Frankel, L. Vora, S. Lau, T. H. Luu, L. Kruper, J. Yim, Y. Yen, F. de
Snoo, R. A. Bender
Brd. 1F Obesity and disease-free survival in patients with nodal-positive early-stage
breast cancer: The ADEBAR trial. (Abstract #541)
P. G. Hepp, B. K. Rack, K. Annecke, A. Wischnik, W. Simon, N. Harbeck,
H. L. Sommer, K. Friese, M. Kiechle, W. Janni, SUCCESS Study Group
Brd. 1G Tamoxifen versus tamoxifen plus octreotide LAR as adjuvant therapy for
early-stage breast cancer in postmenopausal women: Update of NCIC CTG
MA14 trial. (Abstract #542)
M. N. Pollak, J. W. Chapman, K. I. Pritchard, J. E. Krook, H. S. Dhaliwal,
T. A. Vandenberg, T. J. Whelan, S. E. O’Reilly, C. F. Wilson, L. E. Shepherd
Brd. 1H Predictive value of CD24 ala/val polymorphism for pathologic complete
response to sequential anthracycline- and taxane-based neoadjuvant
chemotherapy for primary breast cancer. (Abstract #543)
F. Marme, W. Werft, A. Benner, B. Burwinkel, H. Sinn, C. Sohn, P. Lichter,
M. Hahn, P. Altevogt, A. Schneeweiss
Brd. 2A Prospective randomized trial comparing postoperative adjuvant concurrent
versus sequential hormonal and different radiation fractionation schedule in
breast cancer patients. (Abstract #544)
M. S. Barsoum, M. M. El Mongi, E. M. Khalil, H. E. Eisa, I. M. Hamed, G. A. Attia
Brd. 2B Predictive value of a gene signature evaluated in multiple chemotherapy
regimens for breast cancer. (Abstract #545)
M. Fournier, K. Martin
146